Thematic Exposure -- 8/10
DexCom operates in a textbook CGM duopoly with Abbott (91% combined share) and commands
dominant US prescribed-segment share. The penetration runway is enormous: Type 1 at ~30%,
Type 2 insulin-intensive at less than 5%, and Type 2 non-insulin at less than 1%. The global CGM TAM
is $13.3B today growing to $31B+ by 2031 (15% CAGR), driven by rising diabetes prevalence,
expanding reimbursement, and the emerging wellness/OTC category via Stelo. GLP-1s are proving
to be a demand tailwind rather than headwind -- GLP-1 users adopt CGM at 4x the rate of non-GLP-1
Type 2 patients. The score is not a 9 or 10 because Abbott is gaining share, DexCom is 100%
dependent on a single product category, and several large catalysts (Medicare T2NI coverage,
international parity, Stelo at scale) remain aspirational.
Weight: 25%
Oligopoly Hard Gate: PASS (91% Combined Duopoly Share)
CGM Is a Textbook Duopoly -- DexCom + Abbott Control 91% of Global Shipments
The continuous glucose monitoring market is a tight duopoly between DexCom (~35%
global share) and Abbott (~56% global share), with Medtronic (~7%) as a distant third captive
to its own pump ecosystem. Combined DexCom + Abbott share is ~91%.
US market dynamics: DexCom historically held ~70%+ of the US CGM market (2024 estimate ~74% per iData Research). In the prescribed, reimbursed insulin-using segment (Type 1 + Type 2 IIT), DexCom retains dominant US share, especially in automated insulin delivery (AID) pairings with Omnipod 5, Tandem, and others.
Barriers to entry are very high: FDA PMA regulatory pathway, manufacturing scale, decades of clinical evidence, payer reimbursement relationships, and deep AID ecosystem integration create a durable moat. New entrants (Senseonics implantable, Chinese CGMs) remain niche at less than 2% combined share.
Oligopoly gate: PASS. This is a clear duopoly with 91% combined share and formidable barriers to entry. DexCom is #2 globally but #1 in the highest-value US prescribed segment.
US market dynamics: DexCom historically held ~70%+ of the US CGM market (2024 estimate ~74% per iData Research). In the prescribed, reimbursed insulin-using segment (Type 1 + Type 2 IIT), DexCom retains dominant US share, especially in automated insulin delivery (AID) pairings with Omnipod 5, Tandem, and others.
Barriers to entry are very high: FDA PMA regulatory pathway, manufacturing scale, decades of clinical evidence, payer reimbursement relationships, and deep AID ecosystem integration create a durable moat. New entrants (Senseonics implantable, Chinese CGMs) remain niche at less than 2% combined share.
Oligopoly gate: PASS. This is a clear duopoly with 91% combined share and formidable barriers to entry. DexCom is #2 globally but #1 in the highest-value US prescribed segment.
FY2025 Revenue
$4.66B
+16% YoY
Global CGM TAM (2025)
~$13.3B
Growing to $31B+ by 2031
Duopoly Combined Share
91%
DexCom ~35% + Abbott ~56%
Stelo OTC (FY2025)
~$130M
500K+ users, first full year
Revenue Breakdown -- Geographic Mix (Daloopa, Quarterly)
| Period | US Revenue | Intl Revenue | Total Revenue | US YoY | Intl YoY |
|---|---|---|---|---|---|
| 2024Q1 | $653.2M | $267.8M | $921.0M | +24% | +24% |
| 2024Q2 | $731.9M | $272.4M | $1,004.3M | +19% | +7% |
| 2024Q3 | $701.9M | $292.3M | $994.2M | -2% | +12% |
| 2024Q4 | $802.8M | $310.7M | $1,113.5M | +4% | +17% |
| 2025Q1 | $750.5M | $285.5M | $1,036.0M | +15% | +7% |
| 2025Q2 | $841.0M | $316.1M | $1,157.1M | +15% | +16% |
| 2025Q3 | $851.9M | $357.4M | $1,209.3M | +21% | +22% |
| 2025Q4 | $891.5M | $368.1M | $1,259.6M | +11% | +18% |
FY2025 total: $4.66B (+16% YoY). US ~72%, International ~28%.
Sensor revenue dominates (~97%); hardware declining as G7 eliminates separate transmitter.
Data sourced from Daloopa (company_id: 6704).
Competitive Landscape: Global CGM Market (2025)
| Company | Global Share | Notes | Threat Level |
|---|---|---|---|
| Abbott (Libre) | ~56% | Dominant internationally, especially EU/APAC; strong in Type 2 volume | Primary competitor |
| DexCom (G7/Stelo) | ~35% | Premium positioning; stronger in US; higher share in Type 1/AID | Incumbent #2 global / #1 US Rx |
| Medtronic (Guardian) | ~7% | Captive to Medtronic pump users; shrinking standalone share | Distant third |
| Others (Senseonics, etc.) | <2% | Niche / negligible; implantable and Chinese CGMs | Minimal |
Sources: Mordor Intelligence (2025 shipments), iData Research, company filings.
US share: DexCom ~74% (2024, iData); Abbott gaining with Libre 3 launch.
TAM and Penetration Runway
Global CGM TAM (2025)
~$13.3B
Mordor Intelligence
Global CGM TAM (2031E)
$31B+
15% CAGR
FY2026 Revenue Guide
$5.16-5.25B
Excludes Medicare T2NI upside
US Diabetics (CDC)
38.4M
15.8% adult prevalence
| Segment | CGM Penetration | Population | Status |
|---|---|---|---|
| Type 1 Diabetes | ~30% | Most mature CGM segment | Still 70% of T1 patients not on CGM; steady growth |
| Type 2 Insulin-Intensive (IIT) | <5% | Large and growing population | Coverage expanding; early innings of adoption |
| Type 2 Basal Insulin | Early | Reimbursement expanding | Smart Basal early access Q1 2026; personalized dosing via CGM |
| Type 2 Non-Insulin | <1% | ~12M Medicare beneficiaries | CMS coverage pending (expected 2026); not in guidance = pure upside |
| Wellness / Non-Diabetic (OTC) | Brand new | Entirely new category | Stelo OTC: ~$130M FY2025, 500K+ users, expanding to Amazon/retail |
The penetration gap is the core thesis: even in the most mature segment (Type 1), 70% of patients
are not yet on CGM. In Type 2 (the largest population), penetration is negligible.
Sources: Mordor Intelligence, CDC, IDF, company filings.
Theme 1: GLP-1 as Tailwind, Not Headwind (POSITIVE, HIGH CONVICTION)
GLP-1 Users Adopt CGM at 4x the Rate of Non-GLP-1 Type 2 Patients
Initial market fear was that GLP-1s (Ozempic, Mounjaro, etc.) would reduce CGM demand by
curing diabetes. Evidence points to the opposite.
Key data points:
-- GLP-1 users adopt CGM at 4x the rate of non-GLP-1 Type 2 patients (DexCom/Optum claims data).
-- 100% of surveyed US HCPs recommend CGM + GLP-1 combination therapy.
-- Clinical evidence shows CGM data helps optimize GLP-1 dosing and improves adherence/weight management outcomes.
Mechanism: GLP-1s are expanding the population actively managing metabolic health, which creates CGM demand. Patients on GLP-1s are more engaged in monitoring and more likely to adopt tools that track their metabolic progress.
Long-term caveat: If GLP-1s achieve true diabetes remission at scale (uncertain), some CGM demand could eventually erode. But in the medium term, GLP-1s are clearly additive to the CGM TAM.
Key data points:
-- GLP-1 users adopt CGM at 4x the rate of non-GLP-1 Type 2 patients (DexCom/Optum claims data).
-- 100% of surveyed US HCPs recommend CGM + GLP-1 combination therapy.
-- Clinical evidence shows CGM data helps optimize GLP-1 dosing and improves adherence/weight management outcomes.
Mechanism: GLP-1s are expanding the population actively managing metabolic health, which creates CGM demand. Patients on GLP-1s are more engaged in monitoring and more likely to adopt tools that track their metabolic progress.
Long-term caveat: If GLP-1s achieve true diabetes remission at scale (uncertain), some CGM demand could eventually erode. But in the medium term, GLP-1s are clearly additive to the CGM TAM.
Theme 2: Stelo OTC Expansion (NEW CATEGORY, EARLY)
First FDA-Cleared OTC CGM -- $130M FY2025, 500K+ Users, Expanding to Amazon and Retail
Stelo is the first FDA-cleared over-the-counter CGM, launched mid-2024.
In its first full year (FY2025), Stelo generated ~$130M in revenue with 500K+ users, up from
$22M in partial-year 2024.
Distribution expanding: Amazon, Life Time fitness partnership, and retail channels. International Stelo launch planned for 2026.
Strategic value: Opens an entirely new TAM -- wellness-oriented, non-diabetic consumers who want metabolic insights without a prescription. Low cannibalization risk vs. prescribed G7 (different customer, no Rx required). Contributing ~1% incremental growth to 2026.
Assessment: High-quality optionality in a brand new category. At $130M relative to $4.66B total, Stelo is not yet material, but the OTC consumer health category is nascent and the growth trajectory is encouraging. Scale uncertainty remains -- consumer adoption curves are unpredictable.
Distribution expanding: Amazon, Life Time fitness partnership, and retail channels. International Stelo launch planned for 2026.
Strategic value: Opens an entirely new TAM -- wellness-oriented, non-diabetic consumers who want metabolic insights without a prescription. Low cannibalization risk vs. prescribed G7 (different customer, no Rx required). Contributing ~1% incremental growth to 2026.
Assessment: High-quality optionality in a brand new category. At $130M relative to $4.66B total, Stelo is not yet material, but the OTC consumer health category is nascent and the growth trajectory is encouraging. Scale uncertainty remains -- consumer adoption curves are unpredictable.
Theme 3: Medicare Type 2 Non-Insulin Coverage (BINARY CATALYST)
CMS Coverage Decision Pending -- Would Unlock ~12M Medicare Beneficiaries; Not in 2026 Guidance
Status: CMS coverage decision pending, expected in 2026. Abbott has indicated
first half 2026.
Magnitude: Would unlock approximately 12 million Medicare beneficiaries with Type 2 diabetes who do not use insulin for CGM access. This is the single largest untapped CGM patient population in the US.
DexCom RCT: Randomized controlled trial in Type 2 non-insulin users expected to read out mid-2026, providing additional clinical evidence to support coverage.
Upside framing: This catalyst is not included in DexCom guidance ($5.16B-$5.25B for FY2026), meaning any coverage approval represents pure incremental upside.
Risk: Medicare Type 2 non-insulin coverage has been described as "imminent" for years; further delays are possible.
Magnitude: Would unlock approximately 12 million Medicare beneficiaries with Type 2 diabetes who do not use insulin for CGM access. This is the single largest untapped CGM patient population in the US.
DexCom RCT: Randomized controlled trial in Type 2 non-insulin users expected to read out mid-2026, providing additional clinical evidence to support coverage.
Upside framing: This catalyst is not included in DexCom guidance ($5.16B-$5.25B for FY2026), meaning any coverage approval represents pure incremental upside.
Risk: Medicare Type 2 non-insulin coverage has been described as "imminent" for years; further delays are possible.
Theme 4: International Expansion (LONG RUNWAY)
International at 28% of Revenue Today -- Management Says It Can Become Larger Than US Over Time
International revenue was ~$1.33B in FY2025 (28% of total), with organic growth accelerating
through the year. France was cited as the fastest-growing market in 2025 after Type 2 access expansion.
Tiered product portfolio: G7 (premium), DexCom ONE Plus (value), and Stelo (OTC) allow market-specific pricing and reimbursement strategies. The G7 15-day sensor enables cost-competitive entry into emerging markets where cost-per-day matters.
International Stelo launch planned for 2026, opening the OTC category globally.
Assessment: Abbott currently dominates internationally (~56% global share) with stronger EU/APAC positioning. DexCom has clear room to grow but faces entrenched competition and country-by-country reimbursement hurdles.
Tiered product portfolio: G7 (premium), DexCom ONE Plus (value), and Stelo (OTC) allow market-specific pricing and reimbursement strategies. The G7 15-day sensor enables cost-competitive entry into emerging markets where cost-per-day matters.
International Stelo launch planned for 2026, opening the OTC category globally.
Assessment: Abbott currently dominates internationally (~56% global share) with stronger EU/APAC positioning. DexCom has clear room to grow but faces entrenched competition and country-by-country reimbursement hurdles.
Theme 5: G7 15-Day Sensor and AID Ecosystem (MARGIN + LOCK-IN)
Best Accuracy to Date, Gross Margin Accretive, and Deep AID Integration Creates High Switching Costs
G7 15-day sensor: Broadly available in US as of January 2026. Reduces sensor
changes from ~36/year (10-day) to ~24/year. Same manufacturing cost per sensor means
gross margin accretive on a per-patient basis. Best accuracy to date. Platform
for future products and international expansion.
Smart Basal: Early access launching Q1 2026 -- personalized basal insulin dosing via CGM. Deepens ecosystem lock-in for Type 2 basal patients.
AID integration: DexCom G7 is the CGM of choice for Omnipod 5, Tandem Control-IQ, and other automated insulin delivery systems. This integration creates high switching costs for Type 1 users -- changing CGM means re-validating and re-learning the entire insulin delivery workflow.
Smart Basal: Early access launching Q1 2026 -- personalized basal insulin dosing via CGM. Deepens ecosystem lock-in for Type 2 basal patients.
AID integration: DexCom G7 is the CGM of choice for Omnipod 5, Tandem Control-IQ, and other automated insulin delivery systems. This integration creates high switching costs for Type 1 users -- changing CGM means re-validating and re-learning the entire insulin delivery workflow.
Risks to Theme
| Risk | Description | Severity |
|---|---|---|
| Abbott price competition | Libre is cheaper and gaining share, especially internationally and in pharmacy channel; Libre 4 could narrow the technology gap further | High |
| Coverage timing uncertainty | Medicare Type 2 non-insulin coverage has been "imminent" for years; further delays possible | Medium |
| Utilization mix shift | Lower-acuity Type 2 patients use CGM at 80-85% vs. 90%+ for Type 1 AID; reduces revenue per patient as mix shifts | Medium |
| Stelo scale uncertainty | $130M is still small relative to $4.66B total; OTC consumer adoption curves are unpredictable | Medium |
| 100% CGM concentration | Single product category; no diversification if CGM demand disappoints | Medium |
| GLP-1 long-term unknown | If GLP-1s achieve true diabetes remission at scale (uncertain), some CGM demand could erode | Low-Medium |
Abbott competition is the primary risk: Libre is cheaper, gaining share, and approaching G7 accuracy.
Score Rationale
| Factor | Assessment | Impact |
|---|---|---|
| Oligopoly structure | Duopoly, 91% combined share, high barriers to entry | Very positive (+2) |
| TAM size and growth | $13B growing to $31B+ by 2031 at 15% CAGR | Very positive (+1.5) |
| Penetration runway | Less than 5% in Type 2 (largest segment), massive whitespace | Very positive (+1.5) |
| Secular tailwinds | Diabetes prevalence rising; GLP-1 = demand tailwind (4x adoption) | Positive (+1) |
| OTC / wellness expansion | Stelo opens new category; $130M FY2025; still early | Moderately positive (+0.5) |
| Coverage catalysts | Medicare T2NI pending; not in guidance = pure upside if approved | Positive, binary (+0.5) |
| Competitive position | Abbott gaining share and competing aggressively on price | Moderate concern (-1) |
| Revenue concentration | 100% CGM, single product category | Concentration risk (-0.5) |
| Catalysts still aspirational | Medicare T2NI, international parity, Stelo at scale not yet realized | Slight negative (-0.5) |
8/10 — DexCom operates in a textbook
duopoly (91% combined share) with enormous penetration runway. The CGM TAM is large ($13.3B) and
growing at 15%+ CAGR, driven by rising diabetes prevalence, expanding reimbursement, and the emerging
wellness/OTC category. GLP-1s are proving to be a demand tailwind rather than headwind -- GLP-1 users
adopt CGM at 4x the rate of non-GLP-1 Type 2 patients. The pending Medicare Type 2 non-insulin
coverage decision represents significant upside not in guidance.
The score is not a 9 or 10 because:
(a) Abbott is gaining share and competing aggressively on price, especially internationally and in the pharmacy channel -- Libre 4 could narrow the technology gap further;
(b) 100% CGM concentration -- DexCom has no diversification if CGM demand disappoints;
(c) Several large catalysts remain aspirational -- Medicare T2NI coverage, international parity with Abbott, and Stelo at scale are all still ahead rather than realized.
Base score of 5 + 2.0 (duopoly/barriers) + 1.5 (TAM/growth) + 1.5 (penetration) + 1.0 (GLP-1/secular) + 0.5 (Stelo) + 0.5 (Medicare catalyst) - 1.0 (Abbott competition) - 0.5 (concentration) - 0.5 (aspirational catalysts) = final score of 8. A dominant thematic position with massive runway, tempered by competitive dynamics and execution risk on key catalysts.
The score is not a 9 or 10 because:
(a) Abbott is gaining share and competing aggressively on price, especially internationally and in the pharmacy channel -- Libre 4 could narrow the technology gap further;
(b) 100% CGM concentration -- DexCom has no diversification if CGM demand disappoints;
(c) Several large catalysts remain aspirational -- Medicare T2NI coverage, international parity with Abbott, and Stelo at scale are all still ahead rather than realized.
Base score of 5 + 2.0 (duopoly/barriers) + 1.5 (TAM/growth) + 1.5 (penetration) + 1.0 (GLP-1/secular) + 0.5 (Stelo) + 0.5 (Medicare catalyst) - 1.0 (Abbott competition) - 0.5 (concentration) - 0.5 (aspirational catalysts) = final score of 8. A dominant thematic position with massive runway, tempered by competitive dynamics and execution risk on key catalysts.
Data sourced from Daloopa (company_id: 6704), Mordor Intelligence, iData Research, CDC, IDF, and DexCom company filings / earnings calls.